Humacyte, Inc.
HUMA
$1.29
$0.032.38%
NASDAQ
| 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -23.52% | -6.46% | -26.80% | 2.36% | 23.58% |
| Gross Profit | 26.81% | 7.73% | 29.23% | -2.36% | -23.58% |
| SG&A Expenses | 4.15% | 35.90% | 53.11% | 23.83% | 20.38% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -16.84% | 1.79% | -10.82% | 7.28% | 22.79% |
| Operating Income | 19.33% | -0.77% | 12.77% | -7.28% | -22.79% |
| Income Before Tax | 55.33% | 33.54% | 222.71% | 16.59% | -50.81% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 55.33% | 33.54% | 222.71% | 16.59% | -50.81% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 55.33% | 33.54% | 222.71% | 16.59% | -50.81% |
| EBIT | 19.33% | -0.77% | 12.77% | -7.28% | -22.79% |
| EBITDA | 20.75% | -0.53% | 13.86% | -7.93% | -24.70% |
| EPS Basic | 66.31% | 49.04% | 200.71% | 31.94% | -30.64% |
| Normalized Basic EPS | 45.02% | 20.66% | 68.08% | 19.12% | -7.13% |
| EPS Diluted | 66.31% | 49.52% | 199.66% | 31.94% | -30.64% |
| Normalized Diluted EPS | 45.02% | 20.66% | 68.15% | 19.12% | -7.13% |
| Average Basic Shares Outstanding | 32.58% | 30.43% | 21.60% | 22.56% | 15.43% |
| Average Diluted Shares Outstanding | 32.58% | 30.43% | 21.84% | 22.56% | 15.43% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |